Drug Profile
Flortanidazole F 18
Alternative Names: 18F-flortanidazole; [18F]-HX4; Flortinidazole (18F)Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Siemens AG
- Developer Maastricht University; Siemens AG; Threshold Pharmaceuticals
- Class Nitroimidazoles; Radiopharmaceutical diagnostics; Small molecules; Triazoles
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 29 Jun 2017 Flortanidazole F 18 is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
- 27 Mar 2017 Discontinued - Phase-I for Solid tumours (Diagnosis) in Netherlands (Parenteral)
- 27 Mar 2017 Discontinued - Phase-II for Head and neck cancer (Diagnosis, Metastatic disease, Recurrent) in Australia and USA (Parenteral)